Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Home2026September
Press Release

ClearNote Health to Showcase Power of 5hmC Signatures for Treatment Monitoring at AACR Conference on Pancreatic Cancer

ClearNote Health
September 16, 2026

ClearNote Health to Showcase Power of 5hmC Signatures for Treatment Monitoring at AACR Conference on Pancreatic Cancer

ClearNote Health
September 16, 2026

ClearNote Health Announces Leadership Transition

ClearNote Health
July 9, 2026

Follow us
ClearNote Health logo

Empowering early cancer detection.

Order Test
Company
  • About Us
  • Leadership Team
  • Our News
  • Careers
  • Contact Us
Solutions
  • Avantect Pancreatic Cancer Test
  • Avantect Ovarian Cancer Test
  • Virtuoso Epigenomics Platform
Stay Informed

Get the latest research and announcements from ClearNote Health. Follow us:

Important information: 
The Virtuoso platform is for research use only. Not for use in diagnostic procedures.

The Avantect Pancreatic and Ovarian Cancer Tests are early detection tests. The tests do not establish a diagnosis of pancreatic or ovarian cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic or ovarian cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic or ovarian cancers will be detected. Some patients with pancreatic or ovarian cancer may have a “Pancreatic/Ovarian Cancer Signal not detected” result. Some patients without pancreatic or ovarian cancer may have a “Pancreatic/Ovarian Cancer Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no pancreatic or ovarian cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.

The tests were developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and have not been cleared or approved by the US Food and Drug Administration (FDA).

Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

©2026 ClearNote Health, All Rights Reserved.

Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

  • Privacy Policy
  • Terms of Use
  • Billing rights & protections
  • Cookie Preferences